[5] [6] The medication is a synthetic analog of human GLP-1, modified with an albumin side chain that extends its half-life to approximately one week, allowing for once-weekly subcutaneous administration or daily oral dosing
0.6-0.8% placebo), consistent with the rapid weight loss effect Thyroid C-cell tumors : As with all GLP-1R agonists, tirzepatide carries a boxed warning based on rodent thyroid C-cell tumor findings
Still, 512% of participants discontinued the drug, and the rate was higher at maximum doses
Pre-term birth can pose risks to a baby
Pay attention to how your body respondsincreased appetite suppression on top of post-surgical limitations could prevent adequate calorie intake during a critical healing window
For longer studies, consider whether to reconstitute fresh weekly versus accepting batch-to-batch consistency from a single reconstitution